The trabecular meshwork (TM) is a specialized ocular tissue, which is responsible, together with the Schlemm's canal (SC), for maintaining appropriate levels of intraocular pressure. Dysfunction of these tissues leads to ocular hypertension and increases the risk for developing glaucoma. Previous work by our laboratory revealed dysregulated autophagy in aging and in glaucomatous TM cells. In order to gain more insight in the role of autophagy in the TM pathophysiology, we have conducted transcriptome and functional network analyses of TM primary cells with silenced expression of the autophagy genes Atg5 and Atg7. Atg5/7-deficient TM cells showed changes in transcript levels of several fibrotic genes, including tGfβ2, BAMBI, and SMA. Furthermore, genetic and pharmacological inhibition of autophagy was associated with a parallel reduction in TGFβ-induced fibrosis, caused by a BAMBI-mediated reduced activation of Smad2/3 signaling in autophagy-deficient cells. At the same time, TGFβ treatment led to Smad2/3-dependent dysregulation of autophagy in TM cells, characterized by increased LC3-II levels and autophagic vacuoles content. Together, our results indicate a cross-talk between autophagy and tGfβ signaling in tM cells.
Sigma, 1:5000), SMA (A2547, Sigma, 1:4000), FN1 (sc-8422, Santa Cruz Biotechnologies, 1:500), Smad2/3 (3102S, Cell Signaling, 1:1000), pSmad2/3 (8828S, Cell Signaling, 1:1000),, ColI (Rockland, 600-401-103-0.1, 1:5000), GAPDH (SC-20357, Santa Cruz Biotechnologies, 1:500), β-actin (sc-69879, Santa Cruz Biotechnologies, 1:1500). Blots were scanned, mounted on Adobe Photoshop and analyzed by densitometry with Image J. β-Actin or GAPDH levels for each blot were used for loading control. Unless otherwise indicated, quantitative comparisons were conducted on samples on the same gel. Each specific blot was re-probed without stripping three or four times based on MW of the evaluated proteins and species of secondary antibody to avoid overlapping and recognition of the bands. Membranes were rinsed in 0.1% Tween-20/TBS and re-blocked blocked with 5% nonfat dry milk in 0.1% Tween-20/TBS between the probes. Antibody specificity was assessed by MW of the band and inclusion of positive and negative controls, including specific siRNAs, when possible. Representative images of the different antibodies tested include blots from the same independent experiment. Full-length blots are included as Supplemental Material.
eLiSA. Secreted TGFβ2 in the culture media was quantified by ELISA (Invitrogen) following the instructions provided by the manufacturer. Briefly, culture media was clarified by centrifugation, and latent TGFβ2 activated to the immunoreactive form by incubation for ten minutes at room temperature with 1N HCl, then neutralized with 1.2N NaOH/0.5 M HEPES. TGFβ2 concentrations were normalized to total protein concentration in corresponding whole cell lysates.
GFP-LC3 puncta assay. To monitor autophagy by live cell imaging, were transduced human TM cells with 5 pfu/cell of the replication-deficient adenovirus AdGFP-LC3 (kindly provided by Dr. Wen-Xing Ding, University of Kansas Medical Center). AdGFP was used as a control. Three days after transduction, the cell culture media was changed with TGFβ2 (10 ng/mL)-containing media and the cells were further incubated at 37 °C, 5% CO 2 for 48 h. For starvation condition, the cell culture media was changed with Hank's balanced salt solution (HBSS, GIBCO) and it was incubated for 6 h. Images were acquired with CELENA ® S Digital Imaging System (Logos biosystems) and the images were processed by using Fiji, an image processing package. electron microscopy. Thin sections were prepared as describe in earlier studies 8, 19 . Cells were washed in PBS and fixed in 2.5% glutaraldehyde / 2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.2). Fixed cells were detached by gentle scraping, pelleted, postfixed in 1% osmium tetroxide in 0.1 M cacodylate buffer and processed for transmission electron microscopy in the Morphology Facility at Duke University Eye Center. Thin sections (65 nm) were examined by electron microscopy (JEM-1200EX; JEOL USA, Peabody, MA).
Statistical analysis.
Experiments were performed at least three times using different cell strains from different donors. Data are represented as mean ± SD. Statistical significance was calculated using Student's t-test (*) for two-group comparisons, one-way ANOVA with multiple comparisons ( †) for more than two-group comparisons, or two-way ANOVA with Bonferroni ( ‡) for multiple variables (Prism; GraphPad, San Diego, CA). p < 0.05 was considered statistically significant. Mean values ± SD and P values have been included either in text or, when indicated, in Supplemental Material.
Results

Differential gene expression profile of autophagy-deficient TM cells.
In order to investigate the effects of downregulated autophagy in TM cells, we analyzed gene expression analysis in human TM cells deficient in autophagy. For this, three independent strains of primary human TM cells were transfected with a cocktail of siRNAs to specifically silence the expression of the autophagy genes Atg5 and Atg7 (siAtg5/7). A scrambled siRNA (siNC) was used as control. Downregulated protein levels of Atg5 (30.01 ± 19.97%, p = 0.02, n = 3) and Atg7 (23.33 ± 18.48%, p = 0.01, n = 3) in all the three cell strains were validated by WB at 72 h post-transfection ( Fig. 1A,B ). In addition, siAtg5/7-transfected cultures showed a significant decreased in the levels of the autophagosome marker LC3-II (19.12 ± 18.52%, p = 0.01, n = 3), thus confirming inhibition of autophagy ( Fig. 1A,B ). Changes in whole transcriptome profiling were evaluated by gene array analysis using Affymetrix Human Clariom D chips in conjunction with Partek Flow and Genomic Suite analysis software. Comparative analysis revealed 364 and 298 genes significantly up-regulated and down-regulated, respectively, more than 1.5-fold in autophagy-deficient TM cells compared to control. Tables 1 and 2 show the list of known genes significantly up-and down-regulated, respectively, more than 2-fold in siAtg5/7-compared to siNC-transfected cell. A complete list of genes with differential expression greater than 1.5 fold is included in Supplementary Dataset (Tables S1 and S2 ). Among them, we shall highlight the upregulated expression of TGFβ2 (2.04 fold, p = 0.02) and its pseudoreceptor BMP and activin membrane bound inhibitor (BAMBI) genes (2.17 fold, p = 0.008), as well as the downregulation of the fibrotic marker α-smooth muscle actin (SMA, −1.56 fold, p = 0.003, Table S2 ) in autophagy-deficient TM cells. Figure 1C shows the Partek Flow dot plot visualization of the normalized reads confirming the upregulated expression of TGFβ2 and BAMBI genes in all the three siAtg5/7-transfected cell strains, as well as the expected downregulation of Atg5 and Atg7. Quantitative PCR analysis in additional cell strains confirmed the observed upregulated expression of TGFβ2 (2.11 ± 0.88 fold, p < 0.05, n = 3) and BAMBI (2.14 ± 0.85 fold, p < 0.05, n = 3), as well as the downregulation of SMA (0.475 ± 0.24 fold, p < 0.05, n = 3, Supplementary Dataset - Table S2 ) in siAtg5/7-transfected cells ( Fig. 2A ). Increased total secreted TGFβ2 (0.16 ± 0.05 vs 0.12 ± 0.01 pg/mL/μg, p < 0.05, n = 5) and decreased SMA (54.57 ± 11.24%, p = 0.02, n = 3) protein levels in autophagy-deficient cells compared to siNC were additionally confirmed by ELISA ( Fig. 2B ) and WB (Fig. 2C,D 
Functional network analysis of gene expression changes in autophagy-deficient TM cells.
In order to identify pathways and regulatory elements associated with observed changes in gene expression in autophagy-deficient human TM cells, we further evaluated the gene lists obtained from microarray analysis using MetaCore, a pathway analysis and data mining software. Table 3 shows the top pathways and networks identified in siAtg5/7-transfected human TM cells. Genes with differential gene expression associated to these pathways are listed. As seen, the interferon signaling pathway, angiotensin system, and regulation of endothelial-mesenchymal transition (EMT) were the pathways more significantly enriched in human TM cells with silenced Atg5/Atg7 expression.
Autophagy modulates tGfβ-induced fibrogenesis in TM cells. EMT transition and fibrosis have
been implicated in outflow pathway pathophysiology in glaucoma [21] [22] [23] ; therefore, we decided to further investigate a potential role of autophagy in regulating this particular pathway. As seen earlier, knocking down Atg5 and Atg7 genes resulted in a decrease in the constitutive levels of the EMT/fibrotic marker SMA. Next, we investigated whether silencing of siAtg5/7 could also affect TGFβ-dependent induction of EMT. For this, human TM cells were transfected with siAtg5/7, as detailed earlier, and treated two days after transfection with TGFβ1 or TGFβ2 (10 ng/mL). Protein levels of SMA were evaluated by WB. Cells transfected with siSmad2/3 served as positive control for TGFβ signaling. For clarity, mean values ± SD and P values, as well as densitometric analysis confirming successful knocked down levels have been included in Supplemental Material. As expected, treatment with TGFβs induced the expression of SMA in siNC-transfected cells compared to control, which was blocked in siSmad2/3-deficient cells (Fig. 3A,B ). Interestingly, downregulation of the autophagy genes Atg5 and 7 significantly reduced the TGFβ-dependent increase in SMA. To confirm whether this inhibitory effect was applicable to other EMT-related genes, we additionally looked at the intracellular and secreted protein levels of fibronectin (FN1) and collagen I (Col I). As shown in Fig. 3C -F, silencing Atg5 and Atg7 also decreased the constitutive and the TGFβ-induced expression of FN1 and COL I, although no statistical significance was reached in this later. Atg5 and Atg7 have been reported to fulfill other non-autophagic roles. This raised the question on whether the observed effect of siAtg5/7 on the expression of EMT-related genes was mediated by inhibition of autophagy or, in contrast, through a non-autophagy role of Atg5 or Atg7. To distinguish between these possibilities, we checked SMA and FN1 expression in siLC3-transfected cells ( Fig. 3 ), as well as in TM cells treated with the autophagy inhibitors, 3-MA (10 mM) or BafA1 (100 nM) ( Fig. 4) . In all the three cases, blockage of the autophagy significantly lowered the constitutive and TGFβ-induced levels of SMA ( Fig. 4B and Supplemental Material). siLC3 and more strongly 3-MA also diminished FN1 levels ( Fig. 4C and Supplemental Material). Interestingly, blockage of lysosomal degradation by BafA1 resulted in higher FN1 content, suggesting that intracellular FN1 is targeted for lysosomal degradation.
Upregulation of BAMBI in autophagy-deficient TM cells inhibits TGFβ/Smad signaling. Next,
we investigated activation of TGFβ signaling in autophagy-deficient TM cells by monitoring phosphorylation of Smad2/3 in response to TGFβ2 (10 ng/mL). As seen in Fig. 5A ,B and Supplemental Material 2, siAt-g5/7-transfected cells displayed lower levels of pSmad2/3 upon TGFβ2 treatment compared to control cells, indicating deficient activation of the canonical TGFβ/Smad signaling pathway. Microarray and qPCR analysis showed upregulated expression of BAMBI, an antagonist of TGFβ signaling 24 , with downregulation of Atg5/7 ( Table 2 , Fig. 2A ). We tested whether such upregulation of BAMBI could mediate inhibition of TGFβ/Smad signaling. For this human TM cells were transfected with siAtg5/7 together with siBAMBI for 48 h and then treated with TGFβ2 (10 ng/mL) for 15 min. Interestingly, knocking down BAMBI expression almost enterally restored Fig. 5C ,D). No differences in the levels of total Smad2/3 were observed with downregulation of Atg5/7 and BAMBI. Decrease Atg5 (0.1 ± 0.04 fold, n = 3, p < 0.0001) Atg7 (0.12 ± 0.07 fold, n = 3, p < 0.0001) and BAMBI (0.123 ± 0.068 fold, n = 3, p < 0.0001) mRNA levels in the transfected cells were confirmed by qPCR ( Fig. 5E ). Similarly, no significant changes in Smad2/3 phosphorylation was noted when transfecting siBAMBI in control cells (Supplemental Material). Unfortunately, BAMBI protein levels could not be confirmed since none of the three antibodies tested in our laboratory were capable of recognizing a band of the appropriate molecular weight of human BAMBI when validated with siBAMBI (data not shown).
tGfβ1 and TGFβ2 dysregulate autophagy in a dose-dependent manner. LC3 immunoblot in Fig. 3A showed increased LC3-II in TGFβ1 and TGFβ2-treated cells. We wanted to follow up on this interesting observation. For this, we treated human TM cells with increasing concentrations of TGFβ2 (0, 2, 5, and 10 ng/mL) for 48 h and the levels of LC3-II, as well as of the positive controls SMA and COL I evaluated. As seen in Fig. 6A , TGFβ treatment triggered a dose-dependent increase in LC3-II levels. To discern whether such an increase in LC3-II was the result of autophagy activation or, in contrast, reduced flux, TGFβ treatment was conducted in the absence or presence of BafA1 (100 nM) and levels of p62, an autophagic receptor that is commonly used to monitor autophagic flux, were investigated in addition to those of LC3-II ( Fig. 6B ,C) 25 . Confirming our previous result, treatment with TGFβ1 and TGFβ2 (10 ng/mL) elevated LC3-II levels compared to non-treated cultures ( Fig. 6C and Supplemental Material 2). A decrease in p62 was also observed. As expected, BafA1-treated cells demonstrated increased LC3-II and p62, compared to non-treated ones. However, no further increase, but rather a slight decrease, was observed in combination with TGFβ suggesting potential inhibition of autophagic flux. We further confirmed increased autophagosome number with TGFβ in GFP-LC3 transfected cells as well as in electron micrographs. See elevated number of green-puncta in TGFβ-treated cells, comparable to those observed in cells undergoing starvation (HBSS) not observed with AdGFP control [Fig. 6D , Supplemental Video (t = 10-17 h)], as well as the enhanced presence of autophagic vacuoles in electron micrographs (Fig. 6E) . www.nature.com/scientificreports www.nature.com/scientificreports/ Smad2/3 mediates the dysregulation of autophagy by TGFβ. We next investigated whether the Smad2/3 canonical pathway is involved in the TGFβ-triggered dysregulation of autophagy in human TM cells. For this, we transiently silenced Smad2/3 expression via siRNA and the level of LC3 was analyzed. As seen in Fig. 7A and quantified in Fig. 7B ,C and Supplemental Material, downregulation of Smad2/3 significantly decreased the constitutive and TGFβ-induced increased levels of LC3-II and those of LC3-I. Not significant changes at the messenger level of LC3 was observed with downregulated expression of Smad2/3 (Fig. 7D ).
Discussion
Here, we report for the first time (i) abrogation of TGFβ/Smad signaling in human TM cells deficient in autophagy, mediated by upregulation of BAMBI, (ii) a role of autophagy in regulating TGFβ-induced fibrogenesis, and (iii) the regulation of autophagy by TGFβ in TM cells. Also, ours represents the first study in the literature investigating the comparative gene expression profile of TM cells with silenced autophagy. Development_Regulation of epithelial-to-mesenchymal transition (EMT) 6.453E-04 TGF-beta 2, ACTA2, EDNRA, N-cadherin, PAI1, PDGF-D Table 3 . List of the objects from metacore enrichment analysis, pathway maps.
Silencing of autophagy was achieved by knock down of Atg5 and Atg7 genes, critical molecules for the induction of autophagy, participating in both conjugation cascades leading to LC3 lipidation and autophagosome formation 10 . The choice of silencing both genes together rather than individually came from empirical studies in our laboratory, in which we observed a much higher autophagy inhibition efficiency, close to 100% -as measured by monitoring LC3-II levels -when siRNA targeting those two genes were transfected together or with siLC3. Inhibition of autophagy in TM primary cells lead to significant changes in the transcriptome profile with >600 transcripts showing differential gene expression. Functional network analysis of these genes identified three major signaling pathways affected in Atg5/7-deficient TM cells: interferon signaling pathway, angiotensin system, and regulation of TGFβ-induced EMT. A role of autophagy or autophagy genes in these pathways is supported in the literature. For instance, Atg5 is known to act as a suppressor of innate antiviral immune signaling 26, 27 , therefore it is not surprising to find interferon signaling as the more significant pathway altered in siAtg5/7-transfected cells. A priori, interferon system has not been reported to play a relevant role in outflow pathway pathophysiology, although it cannot be discarded that dysregulation of autophagy could compromise the immune privilege in the anterior chamber of the eye or predispose the trabecular meshwork to pathogen invasion and development of some secondary forms of glaucoma, such as uveitis glaucoma.
More relevant for outflow pathway physiology are the renin-angiotensin system and the EMT pathways. Members of the renin-angiotensin system, including angiotensin-converting enzyme (ACE), angiotensin II and AT1 have been detected in the AH and outflow pathway tissues, and are believed to play a critical role in regulating AH homeostasis 28 . ACE inhibitors have shown efficacy in lowering IOP in animal studies 29, 30 and in human patients with ocular hypertension and glaucoma 31 . The mechanisms and the exact site of action have not been elucidated. Stimulation of prostaglandin synthesis, ECM remodeling and/or fibrogenesis have been proposed 28 .
The role of TGFβ-induced fibrosis and EMT in the pathogenesis of ocular hypertension and glaucoma has been best characterized [21] [22] [23] . Elevated levels of bioactive TGFβ2 are present in the AH from glaucoma patients and are believed to contribute to the increased ECM deposition and fibrosis in the glaucomatous TM 4-6 . Moreover, perfusion of recombinant TGFβ2 in human anterior eye segments or adenoviral gene transfer of constitutively active TGFβ2 in mice and rats elevates IOP and reduces outflow facility 32 . TGFβ2 has been shown to induce TM cell transdifferentiation, as indicated by the expression of the myofibroblast marker SMA and several ECM-related genes (FN1, collagens) [21] [22] [23] . Intriguingly, SMA expression is lost with age and in POAG in vivo despite the presence of active TGFβ2 in the AH 32 . Our data here shows the upregulation and increased secretion of TGFβ2 in TM cells with silenced Atg5 and Atg7. Very interestingly, similar to the reports in the aging and POAG TM, SMA was found to be downregulated in Atg5/7-deficient cells even though the increase in TGFβ2 content. Furthermore, the induction of SMA in response to exogenous TGFβ1 or TGFβ2 treatment was dramatically reduced in siAtg5/7-transfected cultures. This effect was not restricted to SMA, but we also observed a decrease in the constitutive and TGFβ-induced levels of the fibrotic markers FN1 and Col I.
Since autophagy genes are known to play additional non-autophagic roles 33 , we considered the possibility that the observed inhibitory effect could be independent of autophagy. However, silencing LC3 or pharmacological inhibition of autophagy with 3-MA, which blocks autophagosome formation, or BafA1, which blocks autophagic degradation, also diminished constitutive and TGFβ-induced expression of SMA. Interestingly, these two drugs showed a differential effect on FN1 expression. While 3-MA decreased FN1 protein levels, BafA1 treatment increased them. A plausible explanation for this apparent contradicting data is that FN1 is intracellularly degraded within the lysosomes by autophagy; therefore, its levels increases when it can be transported to, but not degraded within the lysosomes. Altogether, the data strongly indicates a role of autophagy in regulating fibrogenesis in TM cells.
An interplay between autophagy and the fibrotic response is recently gaining attention in the literature. Intriguingly, depending on the cell type, tissue or the pathological settings, autophagy can positively or negatively regulate fibrosis. Atg7 knockdown and Atg5 knockout decreased the fibrotic effect of TGFβ in human atrial and mouse embryonic fibroblasts, respectively 34 . Inhibition of autophagy also repressed fibroblast to myofibroblast phenoconversion of primary cardiac fibroblasts 35 . Similarly, autophagy promoted profibrotic effects in hepatic stellate cells and human lung fibroblasts contributing to liver and idiophatic pulmonary fibrosis 36, 37 . Blockage of autophagy by pharmacological and genetic approaches suppressed renal interstitial fibrosis in an in vivo mouse model of unilateral ureteral obstruction 38 . In contrast, silencing Atg5 in the liver during preneoplastic stage facilitated liver fibrosis and tumorigenesis 39 . In a very robust study, Newman et al. conducted global gene expression analysis in adenocarcinoma lung cells with downregulated Atg5 gene expression. Similar to our data, they found the majority of the differentially expressed transcripts to be either direct or indirect targets of transcriptional The regulation of cell signaling by autophagy or "signalphagy" 41 is still an emerging field. Silencing Atg5/7 in TM cells had the same effect as silencing Smad2/3, suggesting that autophagy might regulate fibrosis by abrogating TGFβ/Smad signaling through the selective degradation of a negative regulator. Supporting this, phosphorylation of Smad2/3 in response to TGFβ2 treatment was inhibited in autophagy-deficient TM cells. Intriguingly, BAMBI, an antagonist of TGFβ signaling and inhibitor of BMP signaling 24 , was also found to be significantly upregulated with silenced Atg5 and 7. BAMBI is a transmembrane glycoprotein related to the TGFβ-family type I receptors that lacks the intracellular kinase domain. Overexpression of BAMBI suppresses the effect of TGFβ. More interestingly, BAMBI has been shown to be predominantly degraded through the autophagy lysosomal pathway 42 . BAMBI can negatively regulate TGFβ signaling through different mechanisms. In the cytosol, BAMBI can directly bind to TGFβ-receptors and abrogate Smad2/Smad3 signaling, BAMBI can also form a ternary complex with Smad7/ALK5/ TGFβRI and block Smad3 activation. In association with Smad2/3, BAMBI can translocate into the nucleus and modulate TGFβ-induced transactivation 24 . At the same time, TGFβ can regulate BAMBI transcription by direct binding of Smad3/4 to BAMBI promoter 43 , although a recent report has shown the downregulation of BAMBI following TGFβ2 treatment in TM cells 44 . BAMBI knockdown alters TM ECM expression and reduces outflow facility in mice, being BAMBI proposed as an important regulator of IOP homeostasis 45 , potentially beneficial in glaucoma. Very excitedly, silencing BAMBI expression in siAtg5/7-tranfected cells completely reestablished the levels of pSmad2 in response to TGFβ2 treatment. It is therefore possible that the upregulation of BAMBI in autophagy deficient TM cells could regulate the constitutive and TGFβ-induced www.nature.com/scientificreports www.nature.com/scientificreports/ expression of the fibrotic markers in Atg5/7-deficient TM cells. We are currently developing appropriate tools to further pursue this hypothesis.
Another novel finding here is the Smad2/3-mediated dysregulation of autophagy by TGFβ in TM cells. TGFβ treatment induced a dose-dependent increase in the levels of the autophagosome marker LC3-II, which was completely prevented with silenced Smad2/3 expression. Protein levels of LC3-I were also observed significantly decreased with abolished canonical TGFβ signaling, which pointed towards a potential Smad2/3-regulated transcription of LC3 gene. However, qPCR analysis was not conclusive among the different TM cell strains. An alternative explanation is Smad2/3 to affect the transcription of other Atg genes participant of the pro-LC3 to LC3-I or LC3-I to LC3-II conversions. The increase in LC3-II levels was accompanied by higher number of GFP-LC3 puncta and the presence of autophagic vacuoles, as observed by electron microscopy, in the TGFβ-treated cultures. Although all together indicates activation of autophagy, the decrease in p62 and the fact that no further increase in LC3-II levels were observed in the presence of BafA1 also suggest diminished autophagic flux. Both events do not exclude each other and can occur simultaneously 25 . Modulation of autophagy by TGFβ has been described in other cell types, but the effect seems to be highly cell type-and/or cell context-specific. TGFβ treatment activates autophagy in hepatocellular and mammary carcinoma cell lines 46 , renal tubular epithelial cells 47 , glomerular mesanglial cells and glioma cells 48 . In contrast, TGFβ treatment inhibited autophagy flux during myofibroblast differentiation in lung fibroblasts 49, 50 . As mentioned earlier, numerous studies have confirmed elevated levels of TGFβ2 in the AH of patients with glaucoma. Based on our findings, such increased levels of TGFβ2 can be one of the triggers or contributing factors leading to the previously reported dysregulation of autophagy in In summary, our data here shows for the first time an intricate interplay between autophagy and TGFβ signaling, and a role of autophagy in regulating fibrogenesis via BAMBI and Smad2/3 signalings in TM cells. The implication of autophagy in the induction of the fibrotic response opens a novel area for investigation of therapeutic targets for amelioration of fibrosis in the TM. Future studies will be directed at identifying the exact mechanisms regulating such crosstalk. β-actin was used as loading control. (D) mRNA LC3B and Smad2 fold expression levels quantified by qPCR analysis. † Denotes statistical significance when comparing TGFβ treatment versus control, using one-way ANOVA with multiple comparisons; ‡ denotes statistical significance when comparing TGFβ-treated siSmad2 versus the respective siNC treated control, using two-way ANOVA with Bonferroni post-test. *Denotes statistical significance compared to siNC control using t-test. Specific mean ± SD and p values, as well as densitometric analysis confirming knocked down of Smad2/3 are included in Supplemental Material. RPL: Relative protein levels.
